CFRA views the newly announced $13.1B Johnson & Johnson (JNJ) shockwave deal as positive. David Toung and Sel Hardy discuss the takeaways from Johnson & Johnson’s earnings. The CFRA analyst also notes that they think shares have been under pressure to news that its cough syrup has to be recalled in several African countries. Tune in to find out more about the stock market today.